β_2微球蛋白对急性白血病的预后判断  

β_2 microglobulin levels and prognosis of acute leukemia

作　　者：钟璐[1] 沈璟璟[1] 韩洁英[1] 陈芳源[1] 欧阳仁荣[1] 

机构地区：[1]上海交通大学医学院仁济医院血液科,上海200001

出　　处：《上海交通大学学报（医学版）》2007年第11期1358-1360,共3页Journal of Shanghai Jiao tong University:Medical Science

摘　　要：目的研究血清、尿液β2微球蛋白(β2-MG)对于判断急性白血病预后的价值。方法回顾性分析95例白血病患者初发、缓解、复发时血清、尿液β2-MG水平,分析其与疗效及预后的关系。结果急性髓性白血病(AML)与急性淋巴性白血病(ALL)患者的血、尿β2-MG水平相同(P>0.05)。初发与缓解,复发与缓解的血、尿β2-MG水平有显著差异(P<0.05);而初发与复发的血、尿β2-MG水平相同(P>0.05)。不同年龄、不同染色体核型患者血、尿β2-MG水平有显著差异(P<0.05);但不同性别患者无显著差异(P>0.05)。血、尿β2-MG水平低的患者完全缓解率高、生存期长。结论血、尿β2-MG水平是急性白血病患者有意义的预后指标。Objective To investigate the prognostic value of serum and urine 62 microglobulin（β2-MG） levels in patients with acute leukemia. Methods The serum and urine β2-MG levels at diagnosis, remission and relapse of 95 patients were retrospectively ana- lyzed, and their relationship with efficacy and prognosis was explored. Results There was no difference in the serum and urine β2-MG levels between patients with acute myeloid leukemia （AML） and those with acute lymphatic leukemia （ALL） （ P 〉 0. 05 ）. There were significant differences between the serum and urine β2-MG levels at diagnosis and those at remission, and between those at relapse and those at remission（ P 〈 0.05）. However, there was no significant difference between those at diagnosis and those at relapse（ P 〉 0.05）. There were significant differences in the serum and urine β2-MG levels among those with different ages and chromosome karyotypes（ P 〈 0.05）, while this was not the case between the two genders（P 〉 0.05）. Higher complete remission rate and longer survival term were found in those with lower β2-MG levels. Conclusion β2-MG level is a valuable prognostic indicator for the prognosis of actue leukemia.

关 键 词：Β2微球蛋白 白血病 巴细胞性 髓细胞性 急性 预后指标 

分 类 号：R733.7[医药卫生—肿瘤]